Yusuke Murakami

Gobo, 6440044, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).

Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 05, 2026

Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Journal: Thoracic cancer

Published: September 19, 2025

Study of Sensory Evaluation of Bittering Agents for Establishing an Evaluation System of Bitterness.

Study of Sensory Evaluation of Bittering Agents for Establishing an Evaluation System of Bitterness.

Journal: Journal of food science

Published: August 28, 2025

The Impact of Social Factors on the Duration of Hospitalization for Tuberculosis.

The Impact of Social Factors on the Duration of Hospitalization for Tuberculosis.

Journal: Journal of clinical medicine

Published: July 15, 2025

Effects of Individualized Step Targets on Physical Activity in COPD. A Randomized Study.

Effects of Individualized Step Targets on Physical Activity in COPD. A Randomized Study.

Journal: International journal of chronic obstructive pulmonary disease

Published: July 03, 2025

Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.

Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.

Journal: JTO clinical and research reports

Published: June 16, 2025

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).

Journal: Therapeutic advances in medical oncology

Published: February 07, 2025

Processing of Sedentary Time and Its Reference Equation in Patients with COPD.

Processing of Sedentary Time and Its Reference Equation in Patients with COPD.

Journal: International journal of chronic obstructive pulmonary disease

Published: April 17, 2024

Determinants of Activity Phenotype in Patients with Chronic Obstructive Pulmonary Disease.

Determinants of Activity Phenotype in Patients with Chronic Obstructive Pulmonary Disease.

Journal: International journal of chronic obstructive pulmonary disease

Published: May 19, 2023

Objective Measurement of Physical Activity and Sedentary Behavior in Patients with Chronic Obstructive Pulmonary Disease: Points to Keep in Mind during Evaluations.

Objective Measurement of Physical Activity and Sedentary Behavior in Patients with Chronic Obstructive Pulmonary Disease: Points to Keep in Mind during Evaluations.

Journal: Journal of clinical medicine

Published: March 31, 2023

Validation of Simple Prediction Equations for Step Count in Japanese Patients with Chronic Obstructive Pulmonary Disease.

Validation of Simple Prediction Equations for Step Count in Japanese Patients with Chronic Obstructive Pulmonary Disease.

Journal: Journal of clinical medicine

Published: August 09, 2022

Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.

Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.

Journal: Cancer medicine

Published: February 11, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026